Literature DB >> 31117038

NCCN Guidelines Updates: Management of Prostate Cancer.

James L Mohler, Emmanuel S Antonarakis.   

Abstract

Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer.

Entities:  

Year:  2019        PMID: 31117038     DOI: 10.6004/jnccn.2019.5011

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  29 in total

Review 1.  Race and prostate cancer: genomic landscape.

Authors:  Camilo Arenas-Gallo; Jude Owiredu; Ilon Weinstein; Patrick Lewicki; Spyridon P Basourakos; Randy Vince; Bashir Al Hussein Al Awamlh; Fredrick R Schumacher; Daniel E Spratt; Christopher E Barbieri; Jonathan E Shoag
Journal:  Nat Rev Urol       Date:  2022-08-09       Impact factor: 16.430

2.  Effect of Clinical Parameters on Risk of Death from Cancer after Radical Prostatectomy in Men with Localized and Locally Advanced Prostate Cancer.

Authors:  Daimantas Milonas; Tomas Ruzgas; Zilvinas Venclovas; Daniele Jonusaite; Aivaras Jonas Matijosaitis; Darius Trumbeckas; Edmundas Varpiotas; Stasys Auskalnis; Darijus Skaudickas; Ramunas Mickevicius; Kestutis Vaiciunas; Jonas Mickevicius; Mindaugas Jievaltas
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

3.  Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.

Authors:  Emmanuel S Antonarakis; Jun Luo; Andrew J Armstrong; Landon C Brown; Changxue Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-24       Impact factor: 5.554

4.  Predicting Biochemical Failure in Irradiated Patients With Prostate Cancer by Tumour Volume Measured by Multiparametric MRI.

Authors:  Benedict Oerther; Moritz V Buren; Christina M Klein; Simon Kirste; Nils H Nicolay; Tanja Sprave; Simon Spohn; Deepa Darshini Gunashekar; Leonard Hagele; Lars Bielak; Michael Bock; Anca-L Grosu; Fabian Bamberg; Matthias Benndorf; Constantinos Zamboglou
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

5.  Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology.

Authors:  Jeong Hyeon Lee; Seok Ho Kang; Tae Il Noh; Ji Sung Shim; Sung Gu Kang; Jun Cheon; Jeong Gu Lee
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

Review 6.  Epidemiology and genomics of prostate cancer in Asian men.

Authors:  Yao Zhu; Miao Mo; Yu Wei; Junlong Wu; Jian Pan; Stephen J Freedland; Ying Zheng; Dingwei Ye
Journal:  Nat Rev Urol       Date:  2021-03-10       Impact factor: 14.432

7.  Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study.

Authors:  Eugene B Cone; Stephen Reese; Maya Marchese; Junaid Nabi; Rana R McKay; Kerry L Kilbridge; Quoc-Dien Trinh
Journal:  EClinicalMedicine       Date:  2021-05-06

8.  Current Opinion Regarding Multidisciplinary Cancer Clinic Utilization for the Management of Prostate Cancer.

Authors:  Daniel J Lama; Matthew Kasson; Connor Hoge; Tian Guan; Marepalli Rao; Timothy Struve; Sadhna Verma; Abhinav Sidana
Journal:  J Clin Imaging Sci       Date:  2021-05-28

9.  A Natural Language Processing-Assisted Extraction System for Gleason Scores: Development and Usability Study.

Authors:  Shun Yu; Anh Le; Emily Feld; Emily Schriver; Peter Gabriel; Abigail Doucette; Vivek Narayan; Michael Feldman; Lauren Schwartz; Kara Maxwell; Danielle Mowery
Journal:  JMIR Cancer       Date:  2021-07-02

Review 10.  Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review.

Authors:  Tae Jin Kim; Kyo Chul Koo
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.